1. Protein Tyrosine Kinase/RTK
  2. VEGFR
  3. Parsatuzumab

Parsatuzumab  (Synonyms: 帕萨妥珠单抗; Anti-EGFL7; RG 7414)

目录号: HY-P99215 纯度: 97.40%
Data Sheet SDS COA 技术支持

Parsatuzumab (Anti-EGFL7; RG 7414) 是一种人源化单克隆抗体,作为免疫调节剂与 EGFL7 结合。Parsatuzumab 选择性阻断 EGFL7 与内皮细胞之间的相互作用,可能抑制血管再生,降低血管内皮生长因子 (VEGF) 抑制。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

CAS No. : 1312797-14-0

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥1500
In-stock
5 mg ¥3900
In-stock
10 mg ¥6250
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition[1].

同型

Human IgG1 kappa

推荐同型对照抗体
种属

Humanized

IC50 & Target

VEGF; EGFL7[1]

体外研究
(In Vitro)

EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival[1].
Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: Patient-derived xenograft (PDX) cells
Concentration: /
Incubation Time: 48 hours
Result: Inhibited cell proliferation by 70% from 20%, and resulted in apoptosis increases by 67-87% from 8-17%.
体内研究
(In Vivo)

Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models[1].
Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NSG mice injected with Rec1 cells (s.c.)[2]
Dosage: 50 mg/kg
Administration: Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria
Result: Significantly decreased tumor volume than IgG and increased survival of mice.
CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

帕萨妥珠单抗

运输条件

Shipping with dry ice.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized EGFL7/VE-Statin Protein, Human can bind Parsatuzumab. The EC50 for this effect is 12.19 ng/mL.
纯度 & 产品资料

纯度: 97.94%

参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • 抗体抑制剂请问怎么灭菌呢?

    我们的抗体抑制剂产品本身就是无菌的,细胞实验可以用培养基稀释,动物实验可以用无菌 PBS 或者生理盐水稀释。

  • 抗体抑制剂的人源化,人鼠嵌合抗体有什么区别呢?

    人鼠嵌合抗体由鼠源可变区+人源恒定区组成,人源化约65%,免疫原性较高。人源化抗体仅保留鼠源CDR,其余为人源结构,人源化约90%,免疫原性较低。相比嵌合抗体,人源化抗体更接近人体抗体,安全性更高。

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Parsatuzumab
目录号:
HY-P99215
需求量:
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》